<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04907838</url>
  </required_header>
  <id_info>
    <org_study_id>s-20180040</org_study_id>
    <nct_id>NCT04907838</nct_id>
  </id_info>
  <brief_title>Insulin Stimulated Vasodilation in Patients With Type 2 Diabetes</brief_title>
  <official_title>Insulin Stimulated Vasodilation in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The University of Texas at Arlington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern Denmark</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the role of endothelin in insulin stimulated vasodilation and glucose&#xD;
      uptake. The subjects will complete an hyperinsulinemic euglycemic clamp with and without&#xD;
      blockade of the endothelin receptors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">July 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose infusion rate</measure>
    <time_frame>3.5 hours</time_frame>
    <description>Glucose infusion rate required to maintain euglycemia during insulin clamp with and without endothelin blockade</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Leg blood flow</measure>
    <time_frame>3.5 hours</time_frame>
    <description>Effect of endothelin receptor blockade on leg blood flow (ultrasound Doppler) during insulin clamp with and without endothelin blockade</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Type2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Type 2 diabetics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BQ123 (25 nmol/min), BQ788 (25 nmol/min)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BQ123 (25 nmol/min), BQ788 (25 nmol/min)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin clamp</intervention_name>
    <description>Continous infusion insulin + glucose</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Type 2 diabetics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BQ123</intervention_name>
    <description>Continuous infusion of Insulin + glucose + BQ123</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Type 2 diabetics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BQ123 + BQ788</intervention_name>
    <description>Continous infusion of insulin + glucose + BQ123 + BQ788</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Type 2 diabetics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes OR healthy control (no type 2 diabetes)&#xD;
&#xD;
          -  BMI&lt;32&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  heart disease&#xD;
&#xD;
          -  pregnancy or birth within 3 month&#xD;
&#xD;
          -  smoking&#xD;
&#xD;
          -  Kidney disease&#xD;
&#xD;
          -  beta-blockers&#xD;
&#xD;
          -  insulin treatment (for type 2 diabetics)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Mortensen, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiovascular and Renal Research</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 4, 2019</study_first_submitted>
  <study_first_submitted_qc>May 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2021</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern Denmark</investigator_affiliation>
    <investigator_full_name>Stefan Mortensen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>cyclo(Trp-Asp-Pro-Val-Leu)</mesh_term>
    <mesh_term>BQ 788</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

